



ASX Announcement | 9 October 2020  
Noxopharm Limited (ASX:NOX)

## Noxopharm's CMO Discusses the NOXCOVID trial

**Sydney, 9 October 2020:** Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) releases an FNN interview in which the Chief Medical Officer, Dr Gisela Mautner, discusses the commencement of the Company's COVID-19 trial and also provides a clinical trial program update.

Link to the interview: <https://www.finnewsnetwork.com.au/MediaCenter/MediaCenterMobile.aspx?Site=FNN1875>

The interview will also be found at: <https://www.noxopharm.com/site/investors/presentations>

The related ASX announcement from 2 October 2020 can be found here:

<https://www.noxopharm.com/site/PDF/ec094a4e-a46f-459c-8da7-c2fb7e7495f9/FirstCOVID19PatientTreatedinVeyondaStudy>

*Dr Graham Kelly, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.*

**-ENDS-**

### **About Noxopharm**

Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and septic shock.

Veyonda® is the Company's first pipe-line drug candidate currently in Phase 2 clinical trialling. Veyonda® has two main drug actions – inhibition of sphingosine kinase and inhibition of STING signalling. Activity against the former target contributes to its dual-acting oncotoxic and immuno-oncology functions designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapies, radiotherapy and immune checkpoint inhibitors. Activity against the latter target provides an anti-inflammatory effect, also contributing to an anti-cancer action, but also potentially blocking the development of septic shock.

Noxopharm also is the major shareholder of US biotechnology company Nyrada Inc (ASX:NYR).

To learn more, please visit: [noxopharm.com](http://noxopharm.com)

### **Investor & Corporate enquiries:**

Prue Kelly

M: 0459 022 445

E: [info@noxopharm.com](mailto:info@noxopharm.com)

### **Company Secretary:**

David Franks

T: +61 2 8072 1400

E: [David.Franks@automicgroup.com.au](mailto:David.Franks@automicgroup.com.au)

### **Media Enquiries**

Julia Maguire



The Capital Network

E: [julia@thecapitalnetwork.com.au](mailto:julia@thecapitalnetwork.com.au)

T: + 61 2 8999 3699

**Forward Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.

For personal use only